Wednesday, October 7, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleYahoo Finance· May 11, 2026

Analog Devices (ADI) Outperforms Broader Market: What You Need to Know

View original at finance.yahoo.com
Analog Devices (ADI) Outperforms Broader Market: What You Need to Know Analog Devices (ADI) closed the most recent trading day at $422.73, moving +1.49% from the previous trading session…
Opening lines of the source · Yahoo Finance · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • ADI trades at a Forward P/E of 36.7, a discount relative to the Semiconductor - Analog and Mixed industry average Forward P/E of 55.37.

    60% confidence
  • ADI full-year Zacks Consensus Estimate calls for earnings of $11.35 per share, representing year-over-year growth of +45.7%.

    60% confidence
  • Zacks Rank #1-rated stocks have produced an average annual return of +25% since 1988, validated by third-party audits.

    60% confidence
  • ADI full-year Zacks Consensus Estimate projects revenue of $13.91 billion, representing year-over-year growth of +26.26%.

    60% confidence
  • ADI holds a PEG ratio of 1.68, above the Semiconductor - Analog and Mixed industry average PEG of 1.39.

    60% confidence
  • Analog Devices holds a Zacks Rank of #2 (Buy), supported by a 1.19% upward revision in the Zacks Consensus EPS estimate over the past month.

    60% confidence
  • Analysts expect Analog Devices to post quarterly earnings of $2.88 per share, representing year-over-year growth of 55.68%.

    60% confidence
  • The consensus revenue estimate for the upcoming quarter is $3.51 billion, reflecting a 32.99% rise from the equivalent quarter last year.

    60% confidence
  • ADI's stock has climbed 18.96% in the past month, underperforming the Computer and Technology sector's 19.09% but outpacing the S&P 500's 9.13%.

    60% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Obesity and Immunology Readouts, Big Pharma M&A and AI-Designed Drugs Converge Into a Q4 2026 Catalyst Wave
Late-stage data and deal activity are clustering ahead of Q4 2026. Novo Nordisk's CagriSema won Best Abstract at EASD 2026 for its brain and body (fMRI/MRI) data, Lilly showed ADtouch results for EBGLYSS and agreed to buy Merida Biosciences for $2.9B, and Merck's tulisokibart hit its Phase 2b endpoints. A key regulatory catalyst follows: the FDA PDUFA date for the ivonescimab BLA on 2026-11-14. AI-designed rentosertib showing anti-aging effects adds a speculative AI-drug-discovery thread, while QAIAx's microcities trial and QIII pilot (planned 2027-01-01) are peripheral, forecast-only items.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,351 source documents archived
Query this data → isubstrate.com